Recent publication
Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex
March 1, 2022
Nguyen LH, Leiser SC, Song D, Brunner D, Roberds SL, Wong M, Bordey A. Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex. Epilepsy Res. 2022 Mar;181:106890. doi: 10.1016/j.eplepsyres.2022.106890. Epub 2022 Feb 18. PMID: 35219048; PMCID: PMC8930622.
Brain stimulation treatments in epilepsy: Basic mechanisms and clinical advances
February 1, 2022
Foutz TJ, Wong M. Brain stimulation treatments in epilepsy: Basic mechanisms and clinical advances. Biomed J. 2022 Feb;45(1):27-37. doi: 10.1016/j.bj.2021.08.010. Epub 2021 Sep 2. PMID: 34482013; PMCID: PMC9133258.
Illuminating Seizures: Combined Optical and Electrophysiological Recording Techniques Provide Novel Insights Into Seizure Dynamics
October 20, 2021
Foutz TJ, Wong M. Illuminating Seizures: Combined Optical and Electrophysiological Recording Techniques Provide Novel Insights Into Seizure Dynamics. Epilepsy Curr. 2021 Oct 20;22(1):78-80. doi: 10.1177/15357597211053682. PMID: 35233209; PMCID: PMC8832359.
Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress
September 1, 2021
Zimmer TS, Korotkov A, Zwakenberg S, Jansen FE, Zwartkruis FJT, Rensing NR, Wong M, Mühlebner A, van Vliet EA, Aronica E, Mills JD. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress. Brain Pathol. 2021 Sep;31(5):e12949. doi: 10.1111/bpa.12949. Epub 2021 Mar 30. PMID: 33786950; PMCID: PMC8412124.
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
March 1, 2021
Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O’Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021 Mar 1;78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. PMID: 33346789; PMCID: PMC7754080.